Compares JNJ-79635322 with teclistamab in relapsed or refractory multiple myeloma
Compares JNJ-79635322 with teclistamab in adults with relapsed or refractory multiple myeloma.
Plain-language title generated from the registry record
Registry title: A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Key facts
- Where
- Beijing, Changchun, Chaoyang District, Chengdu, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai, Shenzhen, Tianjin, Tijian, Wenzhou, Wuhan, and Xi'an, ChinaSee the 16 sites
- Phase
- Phase 3
Where in China
- Peking Union Medical College HospitalBeijing, ChinaTaking people
- Peking University First HospitalBeijing, ChinaTaking people
- The First Hospital of Jilin UniversityChangchun, ChinaTaking people
- Beijing Chaoyang HospitalChaoyang District, ChinaTaking people
- Sichuan Academy of Medical Science Sichuan Provincial Peoples HospitalChengdu, ChinaTaking people
- Sun Yat-sen University Cancer CenterGuangzhou, ChinaTaking people
- The First Affiliated Hospital Zhejiang University College of MedicineHangzhou, ChinaTaking people
- The First Affiliated Hospital of NanChang UniversityNanchang, ChinaTaking people
- Nanjing Drum Tower hospitalNanjing, ChinaTaking people
- Shanghai Fourth People's HospitalShanghai, ChinaTaking people
- Peking University Shenzhen HospitalShenzhen, ChinaTaking people
- Tianjin Medical University Cancer Institute and HospitalTianjin, ChinaTaking people
- Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical SciencesTijian, ChinaTaking people
- The First Affiliated Hospital of Wenzhou Medical UniversityWenzhou, ChinaTaking people
- Wuhan Tongji Hospital Tongji Medical CollegeWuhan, ChinaTaking people
- The Second Affiliated Hospital of Xi'an Jiaotong UniversityXi'an, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Janssen Research & Development, LLC
- Trial code
- NCT07518186
- Record updated
- 25 September 2026
- Original description
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.Read full original descriptionShow less
A Phase 3 Randomized Study Comparing JNJ-79635322 Versus Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma After 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.
Inclusion: Documented diagnosis of multiple myeloma (MM) as defined by the criteria below: a. MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria, b. Measurable disease at screening as assessed by central laboratory; Received 1 to 3 prior lines of antimyeloma therapy, including an anti-cluster of differentiation (CD) 38 antibody and lenalidomide; Have an eastern cooperative oncology group (ECOG) performance status of 0 to 2 at screening and immediately before the first dose of study medication; Have clinical laboratory values meeting the criteria specified in the protocol during the screening and within 1 day of the start of administration of study treatment.
Exclusion: Major surgery, (for example, requiring general anesthesia) or significant traumatic injury within 2 weeks prior to first dose, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study; Known active or prior central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required; Suspected or known allergies, hypersensitivity, intolerance or other contraindications to the use of JNJ-79635322 or teclistamab or their excipients; Presence of any of the following: i. Any ongoing myelodysplastic syndrome or B-cell malignancy (other than MM); ii. Any history of malignancy, other than MM, that is considered at high risk of recurrence requiring systemic therapy; iii. Any active malignancy (that is, progressing or requiring treatment change in the last 24 months) other than MM.